Seroprevalence Study on COVID-19

Published: 10 May 2021| Version 1 | DOI: 10.17632/nyd3vj48kf.1


In the current study, we employed a large dataset, including 17,764 participants from Karachi, Lahore, Multan, Peshawar and Quetta, to estimate the seroprevalence of SARS-CoV-2 antibodies and potential predictors of seropositivity. The SARS-COV-2 IgM and/or IgG antibodies were assessed using UNIPER COVID-19 IgG/IgM Rapid Testing Kit, approved by U.S. Food and Drug Administration (US FDA) EUA and certified by European Certified (C.E.) for the qualitative detection of SARS-COV-2 IgM and/or IgG antibodies in human serum. The data represents the Seropositive rates of IgM and IgG antibodies to SARS-CoV-2 antigens. We had also studied the symptom profile of the study subjects and predictors of seropositivity. The SARS-CoV-2 was prevalent in the studied population, considering a high probability of infection among those having close unprotected contact with a confirmed or suspected COVID-19 case, symptoms and who had travelled recently.



Getz Pharma Pvt Ltd